Compare KLIC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLIC | RCUS |
|---|---|---|
| Founded | 1951 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2004 | 2018 |
| Metric | KLIC | RCUS |
|---|---|---|
| Price | $79.75 | $23.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $54.67 | $30.27 |
| AVG Volume (30 Days) | 512.4K | ★ 844.5K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 100.32 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $654,081,000.00 | $247,000,000.00 |
| Revenue This Year | $45.81 | N/A |
| Revenue Next Year | $11.35 | $83.23 |
| P/E Ratio | $249.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.22 | $7.06 |
| 52 Week High | $80.97 | $26.40 |
| Indicator | KLIC | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 70.75 | 56.38 |
| Support Level | $61.26 | $20.18 |
| Resistance Level | N/A | $24.33 |
| Average True Range (ATR) | 2.94 | 1.07 |
| MACD | 1.47 | 0.16 |
| Stochastic Oscillator | 95.91 | 85.79 |
Kulicke & Soffa Industries Inc. is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments, which include Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.